Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| GLOBAL GEOPH | GGS | 7.79% |
| STAAR SURGIC | STAA | 6.23% |
| KAPSTONE PAP | KS | 6.14% |
| HORNBECK OFF | HOS | 5.99% |
| ANIKA THERAP | ANIK | 5.55% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Shares of Dillard’s Inc. (DDS - Analyst Report) have set a new 52-week high of $86.80 on Friday, November 23, 2012, beating its previous 52-week high of $86.71 attained on November 8, 2012. The closing price of this fashion, cosmetics and home furnishings retailer as of November 23, 2012 was $86.44, which represented a marvelous year-to-date return of96.14%. Average volume of shares traded over the last 3 months stands at approximately 436.6 thousand.
Growth Driver
An impressive record of beating the quarterly earnings expectations, sturdy fiscal third quarter 2012 (ended October, 2012) earnings, healthy comparable-store sales, effective cost management, initiatives taken to boost profitability, solid cash flow from operations year-to-date are the major contributors of growth for the shares of this company.
With respect to earnings surprise, Dillard’s has topped the Zacks Consensus Estimates in nine back-to-back quarters, with a solid average of 54.9%.
Dillard's top line (including CDI Contractors LLC or CDI) in the fiscal third quarter 2012 increased 4.8% to $1.450 billion from $1.383 billion in the year-ago quarter. Merchandise sales, excluding CDI, came in at $1.425 billion compared with $1.366 billion in the year-ago quarter. The company’s total revenue (including other income) of $1.486 billion surpassed the Zacks Consensus Estimate of $1.442 billion. Comparable store sales (comps) for the quarter were up 5% year over year.
The robust performance was backed by healthy comparable-store sales growth of 5% and improved margins. Further, management’s cost cutting initiatives are facilitating the company to abridge costs and boost profitability.
The company benefits from improvements in inventory management, which is focused on conservative purchasing and efficiently matching the timing of receipts with demand, thereby resulting in reduced markdowns.
For the nine months ended October 27, 2012, the company generated net cash flow from operations of $219.9 million compared with $135.6 million in the comparable period last year.
Earnings Estimate Revision
The Zacks Consensus Estimate for fiscal 2012 increased 5.5% to $6.33 per share over the last 30 days. The current year-over-year growth estimate for 2012 is 50.4%.
For fiscal 2013, the Zacks Consensus Estimate was raised by 10.8% to $7.20 per share over the same time frame. The current year-over-year growth estimate for 2013 is 13.7%.
Valuation
Dillard's currently trades at a forward P/E of 13.70x, at a premium of 0.3% with the peer group average of 13.66x, while, its price-to-sales ratio of 0.63 is at a premium to the peer group average of 0.57. Moreover, on a price-to-book basis, shares trade at 1.97x versus the peer group average of 1.99x. With respect to return on equity (ROE), the stock looks attractive as well. It has a trailing 12-month ROE of 13.7%, which is above its peer group average of 9.7%. This implies that the company reinvests its earnings more efficiently than its peer group.
About the Company
Headquartered in Little Rock, Arkansas, Dillard's is a large department store chain, featuring fashion apparel and home furnishings. The company’s primary product categories include women’s and junior’s apparel; shoes; accessories and lingerie; men’s clothing and accessories; cosmetics; home; and children’s clothing. Its merchandise mix consists of both branded and private-label items. As of October 27, the company operated 284 outlets and 18 clearance centers and one Internet store across 29 states. The company, founded in 1938, has a market cap of $4 billion.
Zacks Rank & Recommendation
Based on the above analysis, the stock currently carries a Zacks #1 Rank, which translates into a short-term Strong Buy rating for the upcoming 1-3 months. Moreover, we maintain our long-term ‘Outperform’ recommendation on Dillard’s, a peer of Macy’s Inc. (M - Analyst Report).
Get the full Analyst Report on M - FREE
Get the full Analyst Report on DDS - FREE